On Twitter @mitchelzoler
© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
AT THE ESC CONGRESS 2017
On Twitter @mitchelzoler
© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
The ATTRACT trial results contrast with recent reports from another randomized trial, known as CAVENT.
BARCELONA – Study shows women face higher and more persistent risk.
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.